CapForce Inc. · OTC:CFOR
CapForce — Opgen — IPO Roadshow (October 2019)
24 slides from CapForce's IPO roadshow presentation, Oct 18, 2019
Slide 1: OpGen Investment Opportunity Prior to pending business combination with Curetis GmbH
OpGen Investment Opportunity Prior to pending business combination transaction with Curetis GmbH October, 2019 Filed pursuant to Rule 433 Issuer Free Writing Prospectus Registration No. 333 - 233775
Slide 2: Legal Disclaimers for OpGen Inc. Forward Looking Statements
Legal Disclaimers for OpGen Inc. 2 ©2019 OpGen, Inc. Forward Looking Statements T his presentation contains forward - looking statements that are subject to many risks and uncertainties . Forward - looking statements appear in a number of places throughout this presentation and include statements re
Slide 3: OpGen Corporate Overview
OPGEN CORPORATE OVERVIEW ©2019 OpGen, Inc. 3 Precision medicine company focused on combatting the global antibiotic resistance crisis by leveraging molecular diagnostics, informatics, and genomic analysis Provides rapid and actionable information about life threatening drug resistant infections Buil
Slide 4: Curetis Group Corporate Overview
CURETIS GROUP CORPORATE OVERVIEW ©2019 OpGen, Inc. 4 A commercial stage molecular diagnostics company striving molecular microbiology leadership through proprietary platforms and content MDx platforms for low - to high - plex sample - to - answer PCR testing for a broad range of sample types relevan
Slide 5: Combining to Build a Stronger Future
COMBINING TO BUILD A STRONGER FUTURE Strategic Rationale • Establish a leading antimicrobial resistance (AMR) precision medicine business • Broad portfolio of high impact rapid diagnostics and AMR bioinformatics • Leverage combined sales, distribution, bioinformatics and operating infrastructure » C
Slide 6: Transaction Timeline and Conditions to Closing
The transaction is expected to close following approval by shareholders and debt holders for both OpGen and Curetis . Conditions to Closing • Successful completion by OpGen of $10 million equity financing • Both companies will seek approval from their respective shareholders in meetings to be schedu
Slide 7: Strategic Benefits
STRATEGIC BENEFITS Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global commercial channel capabil
Slide 8: Combined Company to Address Multiple High Impact Unmet Clinical Needs
U.S. and European market with high unmet medical need addressable through hospital - focused sales channels COMBINED COMPANY TO ADDRESS MULTIPLE HIGH IMPACT UNMET CLINICAL NEEDS AND LARGE AVAILABLE MARKET OPPORTUNITIES The current Curetis portfolio and pipeline of cartridges according to Curetis man
Slide 9: Combined Company's Portfolio of Commercial Stage Products & Strategic Relationships
COMBINED COMPANY’S PORTFOLIO OF COMMERCIAL STAGE PRODUCTS & STRATEGIC RELATIONSHIPS Unyvero Platform & Tests (Curetis) Unyvero FDA - cleared platform and lower respiratory tract infection (LRT) test Acuitas Tests & Acuitas Lighthouse (OpGen) Acuitas tests in development and pending FDA clearance to
Slide 10: Strategic Benefits
STRATEGIC BENEFITS ©2019 OpGen, Inc. Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global commerci
Slide 11: Sample-to-Answer and High-Throughput Testing Capabilities
Molecular microbiology leadership through proprietary platforms and content SAMPLE - TO - ANSWER AND HIGH - THROUGHPUT TESTING CAPABILITIES * Unyvero A30 RQ Analyzer in development, latest design concept; final product may differ Striving for Molecular Microbiology Leadership MDx Platforms MDx Conte
Slide 12: Current and Near-Term U.S. Product Offerings
CURRENT AND NEAR - TERM U.S. PRODUCT OFFERINGS 12 ©2019 OpGen, Inc. Curetis Unyvero Pneumonia (LRT) OpGen Acuitas AMR Gene Panel Description: ▪ Sample - to - answer multiplex PCR from native specimen in about 5 hours with ~2min hands - on time ▪ 19 multiplexed PCR assays covering 36 Pathogen ID, 10
Slide 13: Curetis' Unyvero A30 RQ Rapid Sample-to-Answer Testing Platform
CURETIS’ UNYVERO A30 RQ RAPID SAMPLE - TO - ANSWER TESTING PLATFORM 13 ©2019 OpGen, Inc. Key Design Features ▪ Fully integrated, closed, sample - to - answer MDx platform ▪ Universal real - time PCR technology for low - to mid - plex testing ▪ Flexible cartridge fluidics for numerous chemistries and
Slide 14: Strategic Benefits
STRATEGIC BENEFITS ©2019 OpGen, Inc. Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global commerci
Slide 15: Ares Genetics & ARESdb
15 ARES GENETICS & ARESdb ©2019 OpGen, Inc. Curetis’ bioinformatics subsidiary with globally leading proprietary AI - powered knowledgebase for AMR informing PCR & NGS - based diagnostics Global ARESdb Database • Leading Knowledgebase on quantitative Antibiotic Resistance Markers building on SIEMENS
Slide 16: Acuitas Lighthouse: Diagnostics Data Management Platform
Cloud - based bioinformatics platform powers our ability to rapidly generate meaningful results that have the potential to change the landscape of clinical management and improve outcomes for patients ACUITAS LIGHTHOUSE®: DIAGNOSTICS DATA MANAGEMENT PLATFORM FOR ANTIBIOTIC RESISTANT PATHOGENS † Rapi
Slide 17: Strategic Benefits
STRATEGIC BENEFITS Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global commercial channel capabil
Slide 18: Commercial Strategy
OpGen and Curetis to realize synergies from a combined commercial effort COMMERCIAL STRATEGY Expanding global c ommercial r each though direct sales in U.S. and global distributors > Direct sales in the U.S. > European distribution through Menarini Diagnostics > China distribution through Beijing Cl
Slide 19: Curetis Pan-European Distribution by Menarini Diagnostics
Starting with 11 EU countries – option to expand relationship to further EMEA markets and additional product lines CURETIS PAN - EUROPEAN DISTRIBUTION BY MENARINI DIAGNOSTICS Menarini Diagnostics Collaboration (Q1 - 2019) > Covers entire Unyvero A50 product line > Initial countries: BE, CH, DE, ES,
Slide 20: Strategic Benefits
STRATEGIC BENEFITS ©2019 OpGen, Inc. Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global commerci
Slide 21: Financial Considerations
FINANCIAL CONSIDERATIONS • We anticipate combined company will be positioned for strong growth profile and sustained value creation • FY2018 revenues of $1.6 million (Curetis) and $2.9 million (OpGen) • Estimated FY2019 combined revenue of $5 - 6 million • Estimated 2020 combined revenue of $10 - 15
Slide 22: Expected Combined Company Governance Team
EXPECTED COMBINED COMPANY GOVERNANCE TEAM Combined team has decades of experience in precision medicine, molecular diagnostics and capital markets Chairman of the Board: William Rhodes Chief Executive Officer: Oliver Schacht, Ph.D. Chief Financial Officer: Timothy C. Dec Board Members: William Rhode
Slide 23: Potential Business Milestones
POTENTIAL BUSINESS MILETONES OpGen / Curetis Business Combination • Successful shareholder votes and debt holder approvals • Closing of business combination transaction Unyvero and Acuitas Rapid DNA tests • FDA clearances and future FDA submissions • Unyvero A30 RQ partnering deal(s) • China NMPA ap
Slide 24: Thank You!
Thank You ! 24 ©2019 OpGen, Inc.